European cancer mortality predictions for the year 2014.
about
Antecolic versus retrocolic reconstruction for prevention of delayed gastric emptying after partial pancreaticoduodenectomyPancreatic cancer from bench to bedside: molecular pathways and treatment optionsHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survivalPancreatic Cancer GeneticsRole of Natural Stilbenes in the Prevention of CancerhERG1 Potassium Channels: Novel Biomarkers in Human Solid CancersThree new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinomaTrends in site- and sex-specific cancer mortality between 1979 and 2010 in Belgium compared with Europe using WHO data.MicroRNA in breast cancer: The association with BRCA1/2.Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trialAnti-apoptotic protein Lifeguard does not act as a tumor marker in breast cancerProcedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies.Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions.Sociodemographic trends in the incidence of pancreatic and biliary tract cancer in UK primary care.Pancreatic surgery: evolution and current tailored approachRole of (64)CuCl 2 PET/CT in staging of prostate cancer.Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors.Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cellsAssessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapyP21 activated kinase-1 mediates transforming growth factor β1-induced prostate cancer cell epithelial to mesenchymal transition.A genome wide association study on Newfoundland colorectal cancer patients' survival outcomesIdentification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.Potential for improvement in cancer management: reducing mortality in the European Union.Role of diet in prostate cancer: the epigenetic link.Lung cancer mortality and years of potential life lost among males and females over six decades in a country with high smoking prevalence: an observational study.Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells.Incidence and Mortality Trends in German Women with Breast Cancer Using Age, Period and Cohort 1999 to 2008Predicting Prostate Biopsy Outcomes: A Preliminary Investigation on Screening with Ultrahigh B-Value Diffusion-Weighted Imaging as an Innovative Diagnostic Biomarker.Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy.Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic StratificationAnti-tumoral effect of desmethylclomipramine in lung cancer stem cells.A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma.Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer.
P2860
Q24187563-035F8767-CEC5-4201-94DD-6D7D07F22EA4Q26747524-633B8DA7-744B-45B5-BFCD-058745F43255Q26747695-44C5C364-6FE9-4F77-AFC9-D0043E6C09E6Q26753854-81B95C3B-EFF1-4EBC-BCDE-BA877288C148Q26765235-7C8F553A-9842-439E-A251-DC64966A085AQ26769976-C5C294B6-ED85-4513-AC09-6273192E80FBQ26784422-84893D3A-F200-44B7-81E1-E041B5DF8B66Q29248193-57B52146-A11B-4DD0-A82E-5236090EC1F8Q30360377-581FC95B-6C3D-4F74-95F2-FC04DB56A954Q30970987-19B07622-2167-4E57-8CAC-A9413F664851Q33364654-ACCC7E34-B274-46F3-AB38-F1D90C903F9EQ33415922-0DC059B0-1B65-4583-A81A-8D6062FD8018Q33439357-DED10EB1-ACE9-4334-B1B0-4E720EC7776DQ33598584-4EE30597-4AF8-4121-8EFF-FFF5A6053C1FQ33840632-F328DB8C-430A-4A79-BEF1-FE5B94DCA4A6Q33891283-B41D5D6F-5DED-4D51-8648-9774B036AF8BQ34277315-3EA10C0F-2E80-4B0C-87D5-8BB217A6D7B7Q34395976-1C78CE95-515D-4A7D-96D9-827B66A2D1E2Q34469877-52814EA4-5C8B-4A1C-A685-1A03AE4907FCQ34492273-A1E771FC-96F2-474F-BEF8-46FDE34901D2Q34607305-789BCF8C-689D-413E-ABAC-2D8463DE1652Q34787165-A7E05706-7265-4BFB-BAAB-02D5615E08F7Q34795689-F15F0CCA-0CD3-4DFD-B2B6-0362B2085EEEQ35218520-9910B57E-8525-4E70-86FA-F0BD710E86B5Q35235907-072A54D1-1F9D-413B-8AE2-2EB134BAE45DQ35368806-B8A355A3-87D9-4366-B34D-F2B5A7E2D680Q35411077-F4DA809F-8415-4040-9DC1-F1E71A2B4584Q35586733-880D83D0-03EF-488E-84D1-74B7B7120E7AQ35768176-4A61DAE6-02CD-4090-92FE-2721A3EC772FQ35836657-84C5B23F-CFEA-4F8E-A42C-A2FA7EC1C24EQ35870320-459DD6E2-5F85-4435-9A8F-8F7FBF49ADA3Q35942650-D31EFFB2-A89E-47F6-B940-A34B03166F6BQ35952787-0C0F90DC-EAB4-4E85-B4CC-CC258680A7D0Q36018511-6AB371A3-0032-423F-8B7E-B9C8BAED7C87Q36149760-1BEAC03F-2A6E-4A83-9B9F-23090260BA4CQ36187546-FD4F839F-3F9F-4520-96C2-F6EBBBF44EB4Q36231919-E93F3812-CBBF-4066-8C09-C337283FEE2FQ36261071-10001742-654D-46D2-9670-73453B92617CQ36284430-91BFEBB7-A1A2-41DB-AE52-1DAD1C7CAD64Q36375417-0E2619E4-3E92-41B7-9D3B-3F479785E92D
P2860
European cancer mortality predictions for the year 2014.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
European cancer mortality predictions for the year 2014.
@ast
European cancer mortality predictions for the year 2014.
@en
European cancer mortality predictions for the year 2014.
@nl
type
label
European cancer mortality predictions for the year 2014.
@ast
European cancer mortality predictions for the year 2014.
@en
European cancer mortality predictions for the year 2014.
@nl
prefLabel
European cancer mortality predictions for the year 2014.
@ast
European cancer mortality predictions for the year 2014.
@en
European cancer mortality predictions for the year 2014.
@nl
P50
P356
P1433
P1476
European cancer mortality predictions for the year 2014.
@en
P2093
P304
P356
10.1093/ANNONC/MDU138
P577
2014-04-23T00:00:00Z